CHD Stock Analysis: Church & Dwight | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 22.523m USD | 12M Return: 8.9% | US1713401024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 169M
EPS Trend: 94.9%
Qual. Beats: 0
Rev. Trend: 95.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Church & Dwight Co., Inc. (NYSE: CHD) develops, manufactures, and markets household, personal care, and specialty products across three reporting segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company sells its consumer goods through supermarkets, mass merchandisers, drugstores, e-commerce channels, and other retail outlets, while specialty products are sold to industrial customers and livestock producers via distributors.
Church & Dwight operates a brand-driven, multi-category portfolio within the consumer staples sector, leveraging flagship names such as ARM & HAMMER, OXICLEAN, WATERPIK, THERABREATH, BATISTE, TROJAN, FIRST RESPONSE, NAIR, ORAJEL, XTRA, ZICAM, HERO, and TOUCHLAND to address everyday household, personal care, and health needs. The company also offers animal nutrition and productivity products-including BIO-CHLOR, FERMENTEN, CELMANAX, and CERTILLUS-used across the poultry, dairy, beef, and swine industries, giving it a niche B2B livestock feed-additives business alongside its consumer-facing operations.
Founded in 1846 and headquartered in Ewing, New Jersey, Church & Dwight is a large-cap household products company that has been publicly traded since 1986. Its model is characteristic of the broader household products sub-industry, where large packaged-goods firms use extensive brand portfolios and broad retail distribution to generate relatively stable, repeat-purchase revenue streams.
- -driven organic sales growth in household and personal care
- TROJAN and WATERPIK personal care outpaces household segment growth
- Acquisition pipeline expands premium oral care and wellness portfolio
| Net Income: 744.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.66 > 1.0 |
| NWC/Revenue: 3.12% < 20% (prev 16.83%; Δ -13.71% < -1%) |
| CFO/TA 0.14 > 3% & CFO 1.26b > Net Income 744.8m |
| Net Debt (2.17b) to EBITDA (1.34b): 1.63 < 3 |
| Current Ratio: 1.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (238.2m) vs 12m ago -3.64% < -2% |
| Gross Margin: 45.65% > 18% (prev 44.47%; Δ 1.18% > 0.5%) |
| Asset Turnover: 69.62% > 50% (prev 69.02%; Δ 0.60% > 0%) |
| Interest Coverage Ratio: 11.43 > 6 (EBIT TTM 1.09b / Interest Expense TTM 95.2m) |
| A: 0.02 (Total Current Assets 1.52b - Total Current Liabilities 1.33b) / Total Assets 9.11b |
| B: 0.77 (Retained Earnings 7.04b / Total Assets 9.11b) |
| C: 0.12 (EBIT TTM 1.09b / Avg Total Assets 8.95b) |
| D: 0.91 (Book Value of Equity 4.35b / Total Liabilities 4.76b) |
| Altman-Z'' = 4.44 = AA |
| DSRI: 0.95 (Receivables 596.8m/611.0m, Revenue 6.23b/6.07b) |
| GMI: 0.97 (GM 44.47% / 45.65%) |
| AQI: 1.16 (AQ_t 0.74 / AQ_t-1 0.64) |
| SGI: 1.03 (Revenue 6.23b / 6.07b) |
| TATA: -0.06 (NI 744.8m - CFO 1.26b) / TA 9.11b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of October 01, 2026, the stock is trading at USD 94.22 with a total of 2,360,176 shares traded. Over the past week, the price has changed by -1.87%, over one month by -5.57%, over three months by -2.45% and over the past year by +8.91%.
Current recommended Stop Loss: 91.70 (which is 2.7% or 1.5 ATR below the current price).
Church & Dwight has received a consensus analysts rating of 3.76. Therefore, it is recommended to hold CHD.
- StrongBuy: 8
- Buy: 2
- Hold: 9
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 105.1 | 11.6% |
P/E Trailing = 30.629
P/E Forward = 23.3645
P/S = 3.6157
P/B = 5.1857
P/EG = 2.6723
Revenue TTM = 6.23b USD
EBIT TTM = 1.09b USD
EBITDA TTM = 1.34b USD
Long Term Debt = 2.21b USD (from longTermDebt, last fiscal year)
Short Term Debt = 75.1m USD (from shortTermDebt, last quarter)
Debt = 2.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.17b USD (calculated: Debt 2.43b - CCE 254.8m)
Enterprise Value = 24.7b USD (22.5b + Debt 2.43b - CCE 254.8m)
Interest Coverage Ratio = 11.43 (Ebit TTM 1.09b / Interest Expense TTM 95.2m)
EV/FCF = 22.14x (Enterprise Value 24.7b / FCF TTM 1.12b)
FCF Yield = 4.52% (FCF TTM 1.12b / Enterprise Value 24.7b)
FCF Margin = 17.90% (FCF TTM 1.12b / Revenue TTM 6.23b)
Net Margin = 11.96% (Net Income TTM 744.8m / Revenue TTM 6.23b)
Gross Margin = 45.65% ((Revenue TTM 6.23b - Cost of Revenue TTM 3.39b) / Revenue TTM)
Gross Margin QoQ = 45.35% (prev 46.38%)
Tobins Q-Ratio = 2.71 (Enterprise Value 24.7b / Total Assets 9.11b)
Interest Expense / Debt = 3.92% (Interest Expense 95.2m / Debt 2.43b)
Taxrate = 21.83% (208.0m / 952.8m)
NOPAT = 850.5m (EBIT 1.09b * (1 - 21.83%))
Current Ratio = 1.15 (Total Current Assets 1.52b / Total Current Liabilities 1.33b)
Debt / Equity = 0.56 (Debt 2.43b / totalStockholderEquity, last quarter 4.35b)
Debt / EBITDA = 1.63 (Net Debt 2.17b / EBITDA 1.34b)
Debt / FCF = 1.95 (Net Debt 2.17b / FCF TTM 1.12b)
Total Stockholder Equity = 4.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.32% (Net Income 744.8m / Total Assets 9.11b)
RoE = 17.78% (Net Income TTM 744.8m / Total Stockholder Equity 4.19b)
RoCE = 17.01% (EBIT 1.09b / Capital Employed (Equity 4.19b + L.T.Debt 2.21b))
RoIC = 11.19% (NOPAT 850.5m / Invested Capital 7.60b)
WACC = 5.43% (E(22.5b)/V(25.0b) * Re(5.69%) + D(2.43b)/V(25.0b) * Rd(3.92%) * (1-Tc(0.22)))
Discount Rate = 5.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -75.44 | Cagr: -1.44%
[DCF] Terminal Value 77.97% ; FCFF base≈1.04b ; Y1≈1.19b ; Y5≈1.76b
[DCF] Fair Price = 102.3 (EV 26.4b - Net Debt 2.17b = Equity 24.3b / Shares 237.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.87 | EPS CAGR: 4.47% | SUE: 0.0 | # QB: 0
Revenue Correlation: 95.23 | Revenue CAGR: 2.48% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.90 | Chg30d=-0.08% | Revisions=-57% | Analysts=15
EPS current Year (2026-12-31): EPS=3.77 | Chg30d=-0.20% | Revisions=+67% | GrowthEPS=+6.8% | GrowthRev=+0.6%
EPS next Year (2027-12-31): EPS=4.04 | Chg30d=-0.12% | Revisions=+8% | GrowthEPS=+7.0% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: +14% (up=11, down=8)